ArticleBlood advances2019
Aspirin inhibits platelets from reprogramming breast tumor cells and promoting metastasis.
Article in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Looking at NSAIDs from a historical perspective and their current status in drug repurposing for cancer treatment and prevention.Journal of cancer research and clinical oncology · 2023Pooled it
- Platelet-derived mitochondrial transfer in cancer metastasis: mechanisms, functional consequences, and translational opportunities.Clinical & experimental metastasis · 2026Review
- Tumor-platelet cross talk in cancer: mechanisms, thrombotic risk, and translational opportunities.Blood advances · 2026Review
- Tumor-Associated Platelets Suppress T-cell Function and Promote Immune Evasion in TNBC via the P-selectin/P-selectin Glycoprotein Ligand 1 Pathway.Cancer research communications · 2026Article
- Platelet-neutrophil cooperation in cancer: mechanisms of metastatic niche formation and implications for prognostic stratification and therapy.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- Investigating the effects of platelets, platelet releasate and aspirin on colorectal cancer cell proliferation, migration and invasion.Medical oncology (Northwood, London, England) · 2026Article
- Ononin suppresses tumor-induced platelet activation and invasion and enhances cell-cycle arrest and apoptosis in triple-negative breast cancer cells.Scientific reports · 2026Article
- Platelet‑circulating tumor cell crosstalk: A pivotal target in cancer diagnosis and therapy (Review).Oncology reports · 2026Review
- Platelets favor the outgrowth of established metastases.Nature communications · 2024Article
- Study on the mechanism of MDSC-platelets and their role in the breast cancer microenvironment.Frontiers in cell and developmental biology · 2024Review
- Review
- Platelets in the tumor microenvironment and their biological effects on cancer hallmarks.Frontiers in oncology · 2023Review
- Drug Repurposing at the Interface of Melanoma Immunotherapy and Autoimmune Disease.Pharmaceutics · 2022Review
- Targeting Platelet Activation Pathways to Limit Tumour Progression: Current State of Affairs.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Review
- Platelets upregulate tumor cell programmed death ligand 1 in an epidermal growth factor receptor-dependent manner in vitro.Blood advances · 2022Article
- Pro-inflammatory megakaryocyte gene expression in murine models of breast cancer.Science advances · 2022Article
- Implementing subtype-specific pre-clinical models of breast cancer to study pre-treatment aspirin effects.Cancer medicine · 2022Article
- Aspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited.Cellular and molecular life sciences : CMLS · 2022Review
- Emerging roles of platelets in cancer biology and their potential as therapeutic targets.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
It is now recognized that compounds released from tumor cells can activate platelets, causing the release of platelet-derived factors into the tumor microenvironment. Several of these factors have been shown to directly promote neovascularization and metastasis, yet how the feedback between platelet releasate and the tumor cell affects metastatic phenotype remains largely unstudied. Here, we identify that breast tumor cells secrete high levels of interleukin 8 (IL-8, CXCL8) in response to platelet releasate, which promotes their invasive capacity. Furthermore, we found that platelets activate the Akt pathway in breast tumor cells, and inhibition of this pathway eliminated IL-8 production. We therefore hypothesized inhibiting platelets with aspirin could reverse the prometastatic effects of platelets on tumor cell signaling. Platelets treated with aspirin did not activate the Akt pathway, resulting in reduced IL-8 secretion and impaired tumor cell invasion. Of note, patients with breast cancer receiving aspirin had lower circulating IL-8, and their platelets did not increase tumor cell invasion compared with patients not receiving aspirin. Our data suggest platelets support breast tumor metastasis by inducing tumor cells to secrete IL-8. Our data further support that aspirin acts as an anticancer agent by disrupting the communication between platelets and breast tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.